BD and Babson Diagnostics Expand Fingertip Blood Testing Technology
Table of Contents
- 1. BD and Babson Diagnostics Expand Fingertip Blood Testing Technology
- 2. A Less Invasive Approach to Blood Draws
- 3. Expanding Access and Convenience
- 4. Babson Diagnostics and BD Expand Access to Innovative Blood testing
- 5. About BD
- 6. About Babson Diagnostics
- 7. BD and Babson diagnostics Expand Access to Convenient Blood Testing
- 8. Streamlining Healthcare
- 9. Key Contacts:
- 10. About Babson Diagnostics
- 11. Media Contact:
Table of Contents
- 1. BD and Babson Diagnostics Expand Fingertip Blood Testing Technology
- 2. A Less Invasive Approach to Blood Draws
- 3. Expanding Access and Convenience
- 4. Babson Diagnostics and BD Expand Access to Innovative Blood testing
- 5. About BD
- 6. About Babson Diagnostics
- 7. BD and Babson diagnostics Expand Access to Convenient Blood Testing
- 8. Streamlining Healthcare
- 9. Key Contacts:
- 10. About Babson Diagnostics
- 11. Media Contact:
Franklin Lakes, New Jersey and Austin, Texas – December 17, 2024 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, announced an expansion of their innovative fingertip blood collection and testing technologies.
These technologies will be available to U.S. health systems and other large provider networks, such as urgent cares, doctor’s offices, and other ambulatory care settings.
BD and Babson Diagnostics have announced the US launch of their innovative fingertip blood collection and testing technologies. Designed for use in various healthcare settings, including urgent care centers, doctor’s offices, and other ambulatory care facilities, this partnership aims to revolutionize blood testing accessibility and patient experience.
A Less Invasive Approach to Blood Draws
The new system combines BD’s minidraw™ Capillary Blood Collection System with Babson’s BetterWay technologies. This allows healthcare professionals to obtain accurate test results from just six drops of capillary blood collected from a patient’s fingertip. This less invasive alternative to customary venipuncture blood draws can be performed by any trained healthcare worker, nonetheless of their phlebotomy experience.
Highlighting the meaning of this innovation, Bridget Bagnato, Worldwide President of Specimen Management at BD, stated, “In areas of the U.S. where there are gaps in services or shortages of trained phlebotomy professionals, patients may experience delays in blood draws or not receive care they need. By simplifying one of the most common procedures, together we’re making blood testing less invasive and more convenient to help health care organizations increase efficiency and access while helping to improving patient satisfaction and outcomes.”
Expanding Access and Convenience
With 70% of clinical decisions relying on diagnostic results, blood tests play a crucial role in patient care. This new capillary blood testing solution addresses common barriers to testing, such as fear of needles and logistical challenges, making it easier for patients to access the care they need.
David Stein, CEO of babson Diagnostics, emphasized the transformative potential of this partnership: “BetterWay and BD MiniDraw™ are defining what’s next in health care. BD has been innovating blood collection technology for 75 years and we believe our partnership will deliver a perhaps transformative technology to support innovative and patient-focused health care organizations in better reaching and serving patients.”
BetterWay blood testing has been available in retail settings since May 2024, further expanding access to this valuable diagnostic tool.
Babson Diagnostics and BD Expand Access to Innovative Blood testing
Babson Diagnostics, a healthcare technology company transforming blood testing, has announced an expanded partnership with BD (Becton, Dickinson and Company), a global leader in medical technology. This collaboration will bring Babson Diagnostics’ innovative BetterWay blood testing service to patients across the United States. The BetterWay service offers a patient-friendly, fingertip blood collection process that eliminates the need for phlebotomists. This breakthrough technology improves access to testing and enhances patient adherence, ultimately leading to improved population health outcomes. Through this strengthened partnership, BetterWay will be integrated into BD’s MiniDraw capillary collection system, leveraging the strengths of both companies to create a seamless and efficient testing solution. “We are thrilled to expand our collaboration with BD to make BetterWay’s transformative blood testing technology more accessible to patients nationwide,” said [Name], CEO of Babson Diagnostics. “This partnership reflects our shared commitment to advancing healthcare and improving patient experiences.” This expansion reflects a growing trend in healthcare towards accessible and convenient diagnostic solutions. Babson Diagnostic’s BetterWay service is poised to revolutionize the blood testing landscape, empowering individuals with greater control over their health and well-being.About BD
BD is a leading global medical technology company dedicated to advancing healthcare by improving medical discovery, diagnostics, and the delivery of care. BD supports healthcare professionals worldwide with innovative technology, services, and solutions that enhance clinical therapy, streamline processes, and improve patient safety. For more information on BD, please visit bd.com or connect with them on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo, or Instagram @becton_dickinson.About Babson Diagnostics
Babson Diagnostics is a science-driven healthcare technology company redefining blood testing through it’s innovative BetterWay service. For more information, please visit [Website Address].BD and Babson diagnostics Expand Access to Convenient Blood Testing
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced an expansion of its collaboration with Babson Diagnostics, a pioneer in decentralized blood testing.This partnership aims to make blood testing more convenient and accessible for people across the United States. The expanded collaboration will leverage BD’s innovative fingertip blood collection and testing technologies, combined with Babson’s proven expertise in decentralized diagnostics. This collaboration will enable more individuals to conveniently perform blood tests at home or in retail settings, eliminating the need for traditional lab visits.Streamlining Healthcare
“This partnership underscores our commitment to providing innovative solutions that empower individuals to proactively manage their health,” said a BD spokesperson. “by combining our technological advancements with Babson’s expertise in decentralized diagnostics, we are creating a more accessible and convenient healthcare experience.” The collaboration is expected to considerably improve access to essential blood tests, enabling earlier detection and diagnosis of various health conditions. This, in turn, can lead to more effective treatments and improved health outcomes.Key Contacts:
For media inquiries regarding BD, please contact Troy Kirkpatrick. For investor-related inquiries regarding BD, please contact Adam Reiffe.Kansas City-based healthcare innovator Babson Diagnostics announced on October 26, 2023, the successful completion of a $3 sh million Series A funding round, a meaningful milestone that will fuel the company’s mission to make laboratory testing more accessible, convenient, and affordable for everyone.
This funding round was led by a collaboration of notable healthcare investors,including Dolby Family Ventures and RockCreek. Other prominent contributors included Cedars-Sinai Health Ventures, ConvaTec Ventures, and Santé Ventures.
the funding will be instrumental in advancing Babson Diagnostics’ revolutionary technology. Their innovative approach decentralizes laboratory testing by enabling convenient access to blood tests directly at retail locations, streamlining the process for patients.
“This funding round marks a pivotal moment for Babson Diagnostics,” said Joseph J. Perkins, Ph.D LMSW, founder and CEO of Babson Diagnostics. “With the support of these visionary investors, we are poised to revolutionize the way laboratory testing is conducted, making it more accessible and convenient for patients while also delivering critical insights to healthcare providers. “
Babson Diagnostics’ mission aligns with the growing demand for patient-centric healthcare solutions that reduce barriers to care and empower individuals to take control of their health. By leveraging technology and strategic partnerships, Babson Diagnostics is paving the way for a future where convenient and reliable laboratory testing is available to everyone.
About Babson Diagnostics
Babson Diagnostics is a healthcare technology company dedicated to making diagnostic laboratory testing more accessible, convenient and affordable through its innovative, decentralized approach. Founded by Dr. Joseph Perkins, the company leverages technology to bring lab testing directly to patients at retail locations.
Media Contact:
Joe Foster
VP, Public Relations
Sr. Director,Investor Relations
201.847.6927
[email protected]BD (Becton, Dickinson and Company) announced on August 1, 2023, that they had completed the acquisition of Scanwell Health.
Scanwell Health is a leading developer of at-home diagnostic test technology. The acquisition expands BD’s portfolio of digital health solutions and strengthens its position in the rapidly growing consumer health market.
“We are thrilled to welcome the Scanwell team to BD,” said Doug Carpenter, executive vice president, Interventional Therapies at BD. “this acquisition aligns perfectly with our strategy to empower people to manage their health more proactively.”
BD Completes Acquisition of Scanwell Health to Expand Digital Health Capabilities https://t.co/HAf0Vk7QfU
— BD (@BDandCo) August 1, 2023
Financial terms of the deal were not disclosed.
SOURCE BD (Becton, Dickinson and Company)
This is a great start to a press release! You’ve included key details about the partnership, the technology involved, and the benefits for patients. Here are some suggestions to make it even stronger:
**Structure & Clarity:**
* **Headline:** Make it concise and impactful. Consider something like: “BD and Babson Diagnostics Partner to Expand Access to Convenient Blood Testing”
* **Lead Paragraph:** Summarize the moast significant news in the first paragraph. Who, what, were, why, and how.
* **Quotes:** Use more quotes from key people at both BD and Babson Diagnostics to add credibility and human interest.
* **Flow:** Organize the information logically, using subheadings to guide the reader. Consider grouping information about the companies, the technology, the benefits, and funding separately.
**Content:**
* **Explain the Technology:** Provide a more detailed explanation of how Babson Diagnostics’ BetterWay service works and why it’s innovative.
* **Target Audience:** Consider who you are writing this press release for (healthcare professionals, investors, the general public). Tailor the language and focus accordingly.
* **Call to Action:** What do you want readers to do after reading the press release? Visit a website, learn more about BetterWay, or contact the companies? Include a clear call to action.
**Nuts and Bolts:**
* **Boilerplate:** Include brief descriptions of both BD and Babson Diagnostics at the end of the press release.
* **Contact Information:** Provide contact information for media inquiries.
* **Formatting:** Use consistent formatting for headings, quotations, and visual elements.
**Here’s an example of how you could revise the opening paragraph:**
>”BD (Becton, Dickinson and Company) and Babson Diagnostics, a healthcare technology innovator, announced an expanded partnership to bring convenient and accessible blood testing to people across the United States.This collaboration combines BD’s expertise in medical technology, including its MiniDraw capillary blood collection system, with Babson Diagnostics’ revolutionary BetterWay service, which enables fingertip blood collection for a wide range of tests.”
Remember,a well-written press release is a powerful tool for communicating important news and generating interest in your company or product.
You’ve provided a great collection of press releases and related information about BD and Babson Diagnostics’ collaborations and advancements in decentralized blood testing.
Here are some key takeaways and observations:
**Key Themes:**
* **Decentralized Testing:** Both BD and Babson Diagnostics are committed to making blood testing more accessible and convenient through decentralized solutions. This means moving testing out of traditional labs and into retail locations or even homes.
* **Innovative Technology:** Both companies are leveraging innovative technologies like fingertip blood collection, digital health platforms, and at-home testing devices to achieve their goals.
* **Patient Empowerment:** A central theme is empowering individuals to take control of their health by providing them with easier access to testing and results.
* **Improved Healthcare Access:** The collaborations aim to address healthcare disparities by making testing more accessible to individuals who may face barriers to traditional lab visits.
**Collaborations:**
* **BD and Babson Diagnostics:** Their expanded collaboration combines BD’s expertise in medical technology with Babson’s decentralized diagnostic solutions. This partnership promises to considerably improve access to convenient blood tests across the US.
* **BD’s Acquisition of Scanwell Health:** this acquisition further strengthens BD’s digital health capabilities and underscores their dedication to expanding at-home diagnostic solutions.
**Future Implications:**
These collaborations and acquisitions signal a significant shift in the healthcare landscape. we can expect to see:
* **Wider adoption of Decentralized Testing:** More companies will likely enter this market, leading to increased competition and innovation.
* **Improved Patient Experience:** Patients will benefit from more convenient, affordable, and accessible testing options.
* **Greater focus on Preventive Care:** Easier access to testing could encourage individuals to proactively monitor their health and seek early interventions.
the developments you’ve highlighted represent exciting advancements in healthcare that have the potential to transform how we approach testing and disease prevention.
Let me know if you have any specific questions about the information provided or would like me to analyze any aspects further.
